Arcturus Announces $50M Investment from Meiji Seika Pharma
Arcturus Therapeutics receives $50 million from Meiji Seika Pharma at an 80% premium. Proceeds will fund ARCT-2601 and validate the LUNAR 2.0 platform amid expanding collaborations with Japanese partners.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed